...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology research and treatment. >A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer
【24h】

A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer

机译：双重癌症患者的单中心回顾性研究：乳腺癌和EGFR-突变体非小细胞肺癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients. EGFR-mutant lung cancer (LC) is a separate molecular subset, and the coexistence of EGFR-mutant LC and BC has not been explored. We hypothesized that EGFR-mutant LC patients could have higher rates of primary BC than those with EGFR-wild type (WT). Methods: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014. Results: Data on treatment, follow-up, and EGFR mutation status were available for 356 patients. 17.7% (11/62) of patients with EGFR mutations had BC, compared to 1.02% (3/294) of EGFR-WT patients (p < 0.001). Both tumors were metachronous in 81.8%, with LC diagnosed 9 years after the diagnosis of BC. 5 of the 6 (83.3%) BC patients treated with radiotherapy developed LC in an area within the radiation field. No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples. Conclusion: SPM in the lung and breast occur more frequently among EGFR-mutant compared to EGFR-WT LC patients. Radiotherapy for BC may increase the risk of developing primary LC. (c) 2019 S. Karger AG, Basel
机译：背景：肺中的第二原始恶性肿瘤（SPM）在乳腺癌（BC）患者中不常见。 EGFR-突变体肺癌（LC）是单独的分子亚特征，并且尚未探讨EGFR-突变体LC和BC的共存。我们假设EGFR-突变体LC患者可能具有比具有EGFR-野生型（WT）的初级BC的速率更高。方法：从2008年至2014年收集了关于LC患者临床和分子特征和女性患者的临床和分子特征和结果的数据，以及我们院治疗的原发性BC的先前或同时历史。结果：治疗，随访和EGFR突变状况的数据适用于356名患者。 17.7％（11/62）的EGFR突变患者具有BC，而EGFR-WT患者的1.02％（3/294）（P <0.001）。两种肿瘤在81.8％中都是相距克的，LC诊断为BC诊断后9年。在辐射场内的一个区域中，用放射疗法治疗的6例（83.3％）的BC患者的5个。在BC组织中检测到EGFR突变，在LC样品中没有检测到HER2表达。结论：与EGFR-WT LC患者相比，EGFR-突变体中的肺和乳房中的SPM更频繁地发生。 BC的放射疗法可能会增加发育初级LC的风险。 （c）2019年S. Karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号